Funded Health Care Startups in Sydney
Among the 14 Sydney Health Care rounds shown, the largest disclosed amount is Sonder’s $25M on 2025-03-10, which stands well above most other disclosed fig…
Among the 14 Sydney Health Care rounds shown, the largest disclosed amount is Sonder’s $25M on 2025-03-10, which stands well above most other disclosed figures. The next-largest disclosed rounds are Neurode at $10M (2025-05-08) and Medinet at $10M (2022-03-17), while several other companies cluster far lower, including Cambium Bio at $2M (2024-12-05), Rosemary Health at $2M (2021-04-07), and multiple sub-$1M disclosed amounts such as Peak Medical’s $60K (2024-08-05).
The disclosed rounds concentrate in a compressed recent window: nine of the 14 entries fall between 2024-05-28 and 2025-05-08, with the most recent being Neurode (2025-05-08) and the oldest being Rosemary Health (2021-04-07). Stage classification is also uneven: six of the 14 rows have “Series Unknown” or blank “series” labels (Amelio Health 2025-02-21 at $400K; Cambium Bio 2024-12-05 at $2M; Touchstone Life Care 2024-07-01 at undisclosed; Avive Health 2023-03-14 at undisclosed; and Sahha 2021-06-08 at $200K). Three additional entries use other disclosed stages (Seed/Pre-Seed/Series A/Corporate Round), and two rounds are “undisclosed,” limiting comparisons at the low end.
Most recent rounds
14 shownRelated listings
Frequently asked
What’s the largest disclosed round here, and how different is it from the rest of the list?
Sonder’s $25M on 2025-03-10 is the largest disclosed amount in the 14-row set, clearly above the next-largest disclosed rounds of $10M (Neurode on 2025-05-08 and Medinet on 2022-03-17). Most other disclosed amounts sit well below that range, including $2M levels for Cambium Bio (2024-12-05) and Rosemary Health (2021-04-07).
Are the rounds clustered into a narrow time window, or spread evenly across the date range shown?
They are clustered toward the most recent period: nine of the 14 entries fall between 2024-05-28 (updoc) and 2025-05-08 (Neurode). The earliest entry shown is Rosemary Health on 2021-04-07, so the list spans roughly 2021-04-07 through 2025-05-08, with heavier activity after mid-2024.
How much of the dataset is hard to compare because the funding stage or amount is missing?
Four of the 14 rows are difficult to benchmark on either stage or size: two have “undisclosed” amounts (Touchstone Life Care on 2024-07-01 and Avive Health on 2023-03-14), and four others use “Series Unknown” or a blank series label (Amelio Health 2025-02-21 at $400K; Cambium Bio 2024-12-05 at $2M; Sahha 2021-06-08 at $200K; plus the two remaining “Series Unknown” entries with disclosed amounts like updoc 2024-05-28 at $13M are still stage-unclear).
Which stages appear, and does any stage category dominate the disclosed set?
Stage labels are mixed rather than dominated by one category: “Series Unknown” or blank appears across multiple entries (including Amelio Health 2025-02-21 at $400K and Sahha 2021-06-08 at $200K), while named stages include Seed (Neurode 2025-05-08 at $10M; Peak Medical 2024-08-05 at $60K; Consultmed 2022-04-16 at $1M; Rosemary Health 2021-04-07 at $2M), and specific non-Seed rounds like Series A (Vantari VR on 2023-12-07 at $7M) and Corporate Round (Medinet on 2022-03-17 at $10M).
Are there notable low-end outliers among the disclosed amounts, given the presence of undisclosed figures?
Among disclosed amounts, Peak Medical’s $60K on 2024-08-05 is the smallest numeric figure shown, below $200K for Sahha (2021-06-08) and $1M rounds like Vively (2022-12-22) and Consultmed (2022-04-16). The presence of undisclosed amounts for Touchstone Life Care (2024-07-01) and Avive Health (2023-03-14) means even lower outcomes could exist, but they can’t be ranked within this table.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.